14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs CGON: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over CG Oncology, Inc. (CGON) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas CGON carries 44.5/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin).
Composite vs. Pillar Nuance: While CGON currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4293.5% operating margin) and revenue trajectory (+0.0% vs. -3.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs CGON. Trailing 12-month operating profitability (SYRE 0.0% vs CGON -4293.5%) and valuation multiples (SYRE N/M vs CGON N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs CGON Key Questions & Quantitative Answers
As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over CG Oncology, Inc. (CGON) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). SYRE carries a Unified Composite Score of 36.1/100 (SELL) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas CGON carries 44.5/100 (HOLD) at $84.94 (N/M Forward P/E, -4293.5% operating margin). Composite vs. Pillar Nuance: While CGON currently prints a higher short-term Unified Composite Score (44.5/100 HOLD vs. SYRE 36.1/100 SELL), SYRE captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4293.5% operating margin) and revenue trajectory (+0.0% vs. -3.7% YoY).
SYRE leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGON at -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $6.2M for CGON. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CGON.
SYRE and CGON trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus CGON (-28.3% ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 89% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.